丹麦外周动脉疾病血运重建后二级预防与心血管结局的时间趋势:全国队列研究
结果显示药物预防使用显著增加,主要不良心血管事件、心肌梗死、心血管死亡和全因死亡风险下降,但大截肢风险无变化。
要点
- 症状性外周动脉疾病血运重建后,阿司匹林、氯吡格雷和他汀使用率随时间显著增加。
- 2013至2016年较2000至2004年,主要不良心血管事件调整风险比为0.73(95%CI 0.62-0.84)。
- 大截肢调整风险比为1.00(95%CI 0.90-1.11),无改善。
核心结论
- 症状性外周动脉疾病血运重建患者的药物预防使用显著增加,除大截肢外所有不良结局均下降。
主要发现
- 2000至2004年与2013至2016年相比,阿司匹林累积使用率从57.3%升至64.3%,氯吡格雷从3.6%升至24.8%,他汀从36.2%升至77.1%。
- 2013至2016年较2000至2004年,主要不良心血管事件调整风险比0.73(95%CI 0.62-0.84),心肌梗死0.60(95%CI 0.48-0.74),心血管死亡0.54(95%CI 0.39-0.76),全因死亡0.80(95%CI 0.72-0.88)。
- 主要不良肢体事件调整风险比0.92(95%CI 0.85-1.00),缺血性卒中0.94(95%CI 0.75-1.18),大出血0.92(95%CI 0.75-1.12),大截肢1.00(95%CI 0.90-1.11)。
临床怎么用
- 对症状性外周动脉疾病血运重建患者应强化阿司匹林、氯吡格雷和他汀等药物二级预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with peripheral arterial disease (PAD) are at increased risk of cardiovascular morbidity and mortality. Medical prevention with antithrombotic and statin therapies is a mainstay of treatment to prevent adverse outcomes; nevertheless, patients with PAD are often undertreated. This study describes the temporal changes in medical prevention and adverse outcomes in a national cohort of patients with symptomatic PAD after revascularization. METHODS: We identified all patients with a first open surgical or endovascular revascularization procedure in the lower extremities or abdomen in Denmark, from 2000 to 2016. We examined temporal changes in the use of aspirin, clopidogrel, and statins and 1-year cause-specific hazard ratios for adverse clinical outcomes, after adjusting for procedure type, treatment indication, age, sex, and cardiovascular risk factors. The analyses were performed overall and within strata of index procedure (endovascular versus surgical), treatment indication, age, sex, and high-risk comorbidities. RESULTS: Between 2000 and 2016, we identified 32 911 patients who underwent revascularization for symptomatic PAD. The mean age was 69 years and increased over time, as did the burden of comorbidity. The cumulative incidence of medication use increased between 2000 to 2004 and 2013 to 2016, respectively, from 57.3% to 64.3% for aspirin, 3.6% to 24.8% for clopidogrel, and 36.2% to 77.1% for statins. Concurrently, the 1-year outcome rates declined. Compared with 2000 to 2004, the adjusted hazard ratios in 2013 to 2016 were 0.73 (95% CI, 0.62-0.84) for major adverse cardiovascular events, 0.92 (95% CI, 0.85-1.00) for major adverse limb events, 0.60 (95% CI, 0.48-0.74) for myocardial infarction, 0.94 (95% CI, 0.75-1.18) for ischemic stroke, 0.92 (95% CI, 0.75-1.12) for major bleeding, 0.54 (95% CI, 0.39-0.76) for cardiovascular death, and 0.80 (95% CI, 0.72-0.88) for all-cause death. These improvements in prognosis were most prominent from 2000 to 2004 to 2005 to 2008 and occurred in all strata of index procedure, treatment indication, sex, age, and comorbidity. In contrast, the adjusted hazard ratio for major amputations was 1.00 (95% CI, 0.90-1.11) when comparing 2013 to 2016 to 2000 to 2004. CONCLUSIONS: Medical prevention of adverse events has increased considerably over time in patients who underwent revascularization for symptomatic PAD. This increase was accompanied by reductions in all adverse outcomes, except major amputations.
引用
- Søgaard M, Nielsen PB, Skjøth F, et al. Temporal Changes in Secondary Prevention and Cardiovascular Outcomes After Revascularization for Peripheral Arterial Disease in Denmark: A Nationwide Cohort Study. Circulation. 2020. PMID: 33300375. doi:10.1161/CIRCULATIONAHA.120.047994
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。